Emerging risks in insurance: Antibiotic resistance

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Tanya Hayward, Emma Hutchinson | 18 July 2019
With the prevalence of antibiotic resistance on the rise and limited innovation in the novel antibiotic space, alternative reimbursement methods can be considered as a potential approach to stimulating innovation and complementing antibiotic stewardship programmes. In the context of antibiotic resistance, de-linkage of profit and volume through the use of an insurance model has been proposed as a potential strategy to stimulate innovation and curb antibiotic resistance through the availability of novel antibiotics.